Skip to main content
SpringerLink
Log in

Herzerkrankungen

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2022

  • 1862 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Aarnoudse AL, Dieleman JP, Stricker BH (2007) Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 30:431–436

    CAS  PubMed  Google Scholar 

  • Ahmed A, Waagstein F, Pitt B, White M, Zannad F, Young JB, Rahimtoola S (2009) Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the digitalis investigation group trial. Am J Cardiol 103:82–87

    CAS  PubMed  Google Scholar 

  • Alexander KP, Weisz G, Prather K, James S, Mark DB et al (2016) Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation 133:39–47

    CAS  PubMed  Google Scholar 

  • Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF et al VICTORIA Study Group (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883–1893

    CAS  PubMed  Google Scholar 

  • Arnold SV, Kosiborod M, McGuire DK, Li Y, Yue P, Ben-Yehuda O, Spertus JA (2014) Effects of ranolazine on quality of life among patients with diabetes mellitus and stable angina. JAMA Intern Med 174:1403–1405

    PubMed  Google Scholar 

  • Barbato E, Herman A, Benit E, Janssens L, Lalmand J et al (2015) Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the MEDCOR trial. Atherosclerosis 240:351–354

    CAS  PubMed  Google Scholar 

  • Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL et al (2005) Amiodaron or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237

    CAS  PubMed  Google Scholar 

  • Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2013) Nationale Versorgungsleitlinie Chronische Herzinsuffizienz. Kurzfassung, 1. Aufl. (Version 7, Dezember 2009, zuletzt geändert: August 2013. AWMF-Reg.-Nr.: nvl/006)

    Google Scholar 

  • Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L et al (2017) Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 19:129–137

    CAS  PubMed  Google Scholar 

  • Castagno D, Petrie MC, Claggett B, McMurray J (2012) Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 33:1137–1141

    CAS  PubMed  Google Scholar 

  • Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M et al (2011) Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365:2268–2276

    CAS  PubMed  Google Scholar 

  • Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e.V. (2017) ESC Pocket Guidelines. Management von Vorhofflimmern, Version 2016. Börm Bruckmeier Verlag GmbH, Grünwald. Kurzfassung der „ESC Guidelines for the Management of Atrial Fibrillation“. Eur Heart J. https://doi.org/10.1093/eurheartj/ehw210

    Article  Google Scholar 

  • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 324:781–788

    CAS  PubMed  Google Scholar 

  • Fanaroff AC, James SK, Weisz G, Prather K, Anstrom KJ et al (2017) Ranolazine after incomplete percutaneous coronary revascularization in patients with versus without diabetes mellitus: RIVER-PCI trial. J Am Coll Cardiol 69:2304–2313

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J et al (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25:1385–1394

    PubMed  Google Scholar 

  • Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816

    CAS  PubMed  Google Scholar 

  • Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R (2014) Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371:1091–1099

    PubMed  Google Scholar 

  • Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM (2010) A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 21:597–605

    PubMed  Google Scholar 

  • Hocini M, Jais P, Sanders P, Takahashi Y, Rotter M et al (2005) Techniques, evaluation, and consequences of linear block at the left atrial roof in paroxysmal atrial fibrillation: a prospective randomized study. Circulation 112:3688–3696

    PubMed  Google Scholar 

  • Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360:668–678

    CAS  PubMed  Google Scholar 

  • Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ (2014) Interaction between digoxin and dronedarone in the PALLAS trial. Circ Arrhythm Electrophysiol 7:1019–1025

    CAS  PubMed  Google Scholar 

  • Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T et al (2012) Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 380:238–246

    CAS  PubMed  Google Scholar 

  • Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L et al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383:1305–1316

    PubMed  Google Scholar 

  • Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S et al (2008) Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358:2678–2687

    PubMed  Google Scholar 

  • Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375:1221–1230

    PubMed  Google Scholar 

  • Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M et al (2020) Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 324:2497–2508

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lehmann G, Reiniger G, Beyerle A, Schomig A (1998) Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine. J Cardiovasc Pharmacol 31:25–30

    CAS  PubMed  Google Scholar 

  • ESC Scientific Document Group, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726

    Google Scholar 

  • McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004

    PubMed  Google Scholar 

  • Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA et al (2010) B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary-thrombolysis in myocardial infarction 36) trial. J Am Coll Cardiol 55:1189–1196

    CAS  PubMed  Google Scholar 

  • Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883

    PubMed  Google Scholar 

  • Olivotto I, Camici PG, Merlini PA, Rapezzi C, Patten M et al (2018) Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail 11:e4124

    Google Scholar 

  • Patten M, Maas R, Bauer P, Luderitz B, Sonntag F et al (2004) Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial. Eur Heart J 25:1395–1404

    PubMed  Google Scholar 

  • Pellicori P, Urbinati A, Shah P, MacNamara A, Kazmi S et al (2017) What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? Eur J Heart Fail 19:768–778

    CAS  PubMed  Google Scholar 

  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. https://doi.org/10.1016/j.rec.2016.11.005

    Article  PubMed  PubMed Central  Google Scholar 

  • Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289:871–878

    CAS  PubMed  Google Scholar 

  • Roy D, Talajic M, Nattel S, Wyse DG, Dorian P et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2677

    CAS  PubMed  Google Scholar 

  • Sanders GD, Hlatky MA, Owens DK (2005) Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353:1471–1480

    CAS  PubMed  Google Scholar 

  • Schmiedl S, Szymanski J, Rottenkolber M, Hasford J, Thürmann PA (2007) Re: Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf 30:1171–1173 (author reply 1173–1174)

    PubMed  Google Scholar 

  • Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609–1620

    CAS  PubMed  Google Scholar 

  • Swedberg K, Komajda M, Böhm M, Borer JS, Ford I (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885

    CAS  PubMed  Google Scholar 

  • Tardif JC (2007) Clinical results of I(f) current inhibition by ivabradine. Drugs 67(Suppl 2):35–41

    PubMed  Google Scholar 

  • Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26:2529–2536

    CAS  PubMed  Google Scholar 

  • The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525–533

    Google Scholar 

  • Vamos M, Erath JW, Hohnloser SH (2015) Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 36:1831–1838

    CAS  PubMed  Google Scholar 

  • Williams VEM (1975) Classification of antidysrhythmic drugs. Pharmacol Ther B 1:115–138

    CAS  Google Scholar 

  • Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380:539–548

    CAS  PubMed  Google Scholar 

  • Wagner F, Gohlke-Barwolf C, Trenk D, Jähnchen E, Roskamm H (1991) Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris. Eur Heart J 12:994–999

    CAS  PubMed  Google Scholar 

  • Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M et al (2016) Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 387:136–145

    CAS  PubMed  Google Scholar 

  • Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833

    CAS  PubMed  Google Scholar 

  • Zareba W, Daubert JP, Beck CA, Huang DT, Alexis JD et al (2018) Ranolazine in high-risk patients with implanted cardioverter-defibrillators: the RAID trial. J Am Coll Cardiol 72:636–645

    CAS  PubMed  Google Scholar 

  • Zhu W, Mazzanti A, Voelker TL, Hou P, Moreno JD et al (2019) Predicting patient response to the antiarrhythmic mexiletine based on genetic variation. Circ Res 124:539–552

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P et al (2015) Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 351:h4451

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    Prof. Dr. med. Thomas Eschenhagen

  2. Medizinische Klinik II, Sana Kliniken Lübeck, Kronsforder Allee 71-73, 23560, Lübeck, Deutschland

    Prof. Dr. med. Joachim Weil

Authors
  1. Prof. Dr. med. Thomas Eschenhagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Joachim Weil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Eschenhagen .

Editor information

Editors and Affiliations

  1. Arzneimittelkommission der deutschen Ärzteschaft, Berlin, Deutschland

    Wolf-Dieter Ludwig

  2. Institut für Pharmakologie, Klinikum Bremen-Mitte, Bremen, Deutschland

    Bernd Mühlbauer

  3. Institut für Pharmakologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    Roland Seifert

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Eschenhagen, T., Weil, J. (2022). Herzerkrankungen. In: Ludwig, WD., Mühlbauer, B., Seifert, R. (eds) Arzneiverordnungs-Report 2022. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-66303-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-66303-5_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-66302-8

  • Online ISBN: 978-3-662-66303-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation